Key MessageAlthough ASP8273 was well tolerated and promoted antitumor activity in prior early phase studies in patients with *EGFR*-mutated lung cancer with disease progression on prior EGFR TKI therapy, ASP8273 was not superior to a first-generation tyrosine kinase inhibitor in the current phase III study.

Introduction
============

The incidence of *epidermal growth factor receptor* (*EGFR*) gene mutations in patients with non-small-cell lung cancer (NSCLC) is 10% in Europe/North America and 30% in Asia \[[@mdz128-B1]\]. Activating mutations, including deletions in exon 19 and L858R point mutations in exon 21, account for ∼90% of *EGFR* mutations in NSCLC \[[@mdz128-B2]\]. *EGFR* regulates tumor cell survival, proliferation, angiogenesis, and invasion; activating *EGFR* mutations (e.g. L858R) are associated with increased survival and responses to tyrosine kinase inhibitor (TKI) therapy \[[@mdz128-B3], [@mdz128-B4]\]. Growing evidence also suggests that *EGFR* mutations are predictive of clinical responses. For example, T790M mutations are associated with a failure to respond to TKI therapy; ≥50% of patients with NSCLC resistant to erlotinib/gefitinib acquire T790M mutations \[[@mdz128-B4], [@mdz128-B5]\]. Targeting both *EGFR* activating and T790M mutations with osimertinib demonstrated superior efficacy to the current standard-of-care EGFR-targeting TKI therapies (erlotinib and gefitinib), with a similar safety profile and fewer serious adverse events \[[@mdz128-B6]\].

ASP8273 is a novel, small molecule, irreversible TKI that inhibits *EGFR* activity in patients with exon 19 deletions, L858R substitutions in exon 21, as well as T790M resistance mutations \[[@mdz128-B7], [@mdz128-B8]\]. In early phase studies, ASP8273 demonstrated antitumor activity in patients with *EGFR* mutation-positive NSCLC. In a first-in-human study in Japanese patients, median progression-free survival (PFS) was 5.6 months \[95% confidence interval (CI) 3.6--11.1\] and the overall response rate (ORR) was 49% (95% CI 33.7--64.2) in patients treated with 25--600 mg ASP8273 \[[@mdz128-B7]\]. In North American patients with *EGFR* T790M mutations who progressed after prior TKI therapy (treated with 25--500 mg ASP8273), median PFS was 6.8 months (95% CI 5.5--10.1 months) and the ORR was 31.0% (95% CI 19.5--44.5) \[[@mdz128-B9]\].

This phase III study assessed the efficacy, safety, and tolerability of ASP8273 versus erlotinib/gefitinib in patients with newly diagnosed or recurrent locally advanced, metastatic, or unresectable stage IIIB/IV adenocarcinoma NSCLC with *EGFR* activating mutations not previously treated with an EGFR inhibitor.

Methods
=======

Study design
------------

This global, phase III, open-label, randomized study (NCT02588261) included eligible patients with histologically confirmed advanced/metastatic or unresectable stage IIIB/IV adenocarcinoma NSCLC, an Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤2, and a life expectancy of ≥12 weeks. Previously untreated patients with activating *EGFR* mutations (exon 19 deletion or exon 21 L858R), with or without T790M or other rare *EGFR* mutations associated with lower sensitivity or resistance were eligible; those harboring both exon 19 deletions and L858R were not. Patients were randomized based on local mutation status and remained on study if central results were discordant. Patients could not have symptomatic central nervous system metastases or prior *EGFR*-targeting therapy, or prior chemotherapy for metastatic disease (except palliative local radiation for painful bone metastases completed ≥1 week before the first dose of study drug). The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, the International Council for Harmonisation, and Good Clinical Practice Guidelines. Informed consent was obtained from all patients.

Eligible patients were randomized (1 : 1) via interactive response technology to either the ASP8273 or erlotinib/gefitinib arms. Randomization was stratified by ECOG PS (0 versus 1 versus 2), *EGFR* mutation type (exon 19 deletion versus L858R mutation in exon 21), choice of TKI (erlotinib versus gefitinib), and race (Asian versus non-Asian) ([supplementary Figure S1](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). Investigators selected erlotinib/gefitinib before site initiation or shipment of study drug. ASP8273 300 mg, erlotinib 150 mg, or gefitinib 250 mg was administered orally once daily. Concomitant medications were not administered within 2 h of dosing with ASP8273, erlotinib, or gefitinib.

An independent data monitoring committee (IDMC), chartered at study initiation to oversee safety, carried out an interim safety and futility analysis from 417 randomized patients (ASP8273, *n *=* *209; erlotinib/gefitinib, *n *=* *208). During the futility analysis, the predictive probability that the response rate would be higher in patients receiving ASP8273 compared with erlotinib/gefitinib if all 600 subjects are enrolled was 0.00009. Therefore, on 4 May 2017, the IDMC recommended stopping the study before it was fully enrolled based on increased toxicity and limited predicted efficacy of ASP8273 relative to erlotinib/gefitinib. After study discontinuation, patients receiving erlotinib/gefitinib entered a 3-month transition period. No new patients were enrolled in ASP8273 studies, but patients with exon 20 point mutations from another phase I study (NCT02113813) without available standard-of-care therapies could continue ASP8273 under revised consent parameters.

Datasets with scrambled treatment codes were transferred to prepare analysis programs. Randomized treatment codes were not transferred to statistical programmers, the study statistician, or supporting statisticians before the database lock, nor did these individuals have direct access to randomized treatment information before the database lock. Only study managers and team members had access to individual patient treatment information.

End points and assessments
--------------------------

The primary end point was PFS based on blinded, independent radiologic review (IRR). Secondary end points included investigator-assessed PFS, best ORR \[complete responses (CR) +partial responses (PR)\], disease control rate \[CR +PR +stable disease (SD)\], duration of response (DoR), and the safety and tolerability profile. Responses were assessed every 8 weeks (±7 days) throughout the duration of the study.

The full analysis set (FAS) represents all randomized patients and was used for efficacy analyses. The safety analysis set (SAF) included all patients taking ≥1 dose of study drug and was used for statistical summaries of safety data. The distribution of PFS was estimated using Kaplan--Meier methodology. A stratified Cox proportional hazard model estimated hazard ratios and corresponding 95% CI. Response and progression were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The statistical analysis plan was finalized before study unblinding, database lock, interim analysis, or accumulation of substantial data. Approximately 600 patients were planned to be randomized. Assuming a hazard ratio of 0.667 (median PFS in the 8273 and erlotinib/gefitinib arm were 15.6 and 10.4 months, respectively), 420 PFS events would provide ∼98.7% power to detect a statistically significant difference at type I error rate of one-sided 0.025.

Results
=======

Patients
--------

This study was conducted between 11 February 2016 and 21 December 2017 at 201 sites across 23 countries worldwide. A total of 812 patients were screened and signed informed consent; 282 (34.7%) patients discontinued before randomization. A total of 530 patients were randomized; 267 patients received ASP8273 and 263 received erlotinib (*n *=* *151) or gefitinib (*n *=* *112) (Figure [1](#mdz128-F1){ref-type="fig"}). Of enrolled patients, 99.4% (*n *=* *527) received ≥1 dose of study drug. In the FAS (*n *=* *530), reasons for discontinuation included termination of study by sponsor (57%; *n *=* *298), disease progression (27%; *n *=* *143), adverse events (10%; *n *=* *53), and death (\<1%; *n *=* *3).

![Patient disposition.](mdz128f1){#mdz128-F1}

Patient demographics and baseline disease characteristics were similar between both treatment arms (Table [1](#mdz128-T1){ref-type="table"}). The median age was 67 years (range 23--89 years) and ∼61% (*n *=* *324) were female. Among all patients, 49.6% (*n *=* *263) had investigator-assessed exon 19 deletions, 41.3% (*n *=* *219) had an L858R mutation, and 1.9% (*n *=* *10) had a T790M mutation. Most patients (96.8%; *n *=* *513) had an ECOG PS ≤1 and 64.5% (*n *=* *342) never used tobacco.

###### 

Demographic and baseline characteristics (FAS)

                                                                  ASP8273         Erlotinib/ gefitinib   Total
  --------------------------------------------------------------- --------------- ---------------------- ---------------
  Median age, years (range)                                       68 (32--88)     67 (23--89)            67 (23--89)
  Sex, *n* (%)                                                                                           
   Male                                                           96 (36.0)       110 (41.8)             206 (38.9)
   Female                                                         171 (64.0)      153 (58.2)             324 (61.1)
  Median time from diagnosis, days (range)                                                               
   Duration from initial diagnosis                                50 (15--3303)   44 (10--3663)          47 (10--3663)
   Duration from locally advanced/ metastatic disease diagnosis   37 (3--1432)    36 (4--1525)           36 (3--1525)
  Most recent NSCLC stage, *n* (%)                                                                       
   Stage IIIB                                                     14 (5.2)        16 (6.1)               30 (5.7)
   Stage IV                                                       251 (94.0)      247 (93.9)             498 (94)
   Missing                                                        2 (\<1)         0                      2 (\<1)
  *EGFR* mutation type, *n* (%)                                                                          
   Exon 19 deletion                                               134 (50.2)      129 (49.0)             263 (49.6)
   Exon 21 *L858R*                                                111 (41.6)      108 (41.1)             219 (41.3)
   *T790M*                                                        4 (1.5)         6 (2.3)                10 (1.9)
  ECOG PS, *n* (%)                                                                                       
   0                                                              103 (38.6)      103 (39.2)             206 (38.9)
   1                                                              155 (58.1)      152 (57.8)             307 (57.9)
   2                                                              9 (3.4)         8 (3.0)                17 (3.2)
  Tobacco history, *n* (%)                                                                               
   Never                                                          171 (64.0)      171 (65.0)             342 (64.5)
   Current                                                        12 (4.5)        9 (3.4)                21 (4.0)
   Former                                                         84 (31.5)       83 (31.6)              167 (31.5)

One hundred and fifty-one patients received erlotinib and 112 received gefitinib.

ECOG PS, Eastern Cooperative Oncology Group performance status; *EGFR*, epidermal growth factor receptor; FAS, full analysis set; NSCLC, non-small-cell lung cancer.

Efficacy
--------

At the time of this interim analysis, there were 107 PFS events assessed by IRR (*n *=* *61, 22.8% for ASP8273 and *n *=* *46, 17.5% for erlotinib/gefitinib). Median duration of follow-up was 3.5 months for patients receiving ASP8273 and 3.6 months for those receiving erlotinib/gefitinib. Median PFS was 9.3 months (95% CI 5.6--11.1 months) in patients receiving ASP8273 and 9.6 (95% CI 8.8--NE) in those receiving erlotinib/gefitinib, with a hazard ratio of 1.611 (*P *=* *0.992) (Figure [2](#mdz128-F2){ref-type="fig"}). The 6-month PFS rate was 57% (95% CI 46.8--66.0) for ASP8273 and 76% (95% CI 66.6--82.7) in erlotinib/gefitinib; the 12-month PFS rate was 29% (95% CI 12.8--47.5) and 38% (95% CI 20.8--55.5), respectively.

![Progression-free survival (FAS). CI, confidence interval; FAS, full analysis set.](mdz128f2){#mdz128-F2}

No CR were seen in either treatment arm (Table [2](#mdz128-T2){ref-type="table"}). Fewer patients receiving ASP8273 achieved PR (33% versus 48%) versus those receiving erlotinib/gefitinib, but more had SD (29% versus 18%). The ORR in patients treated with ASP8273 was 33% (95% CI 27.4--39.0); patients receiving erlotinib/gefitinib had an ORR of 47.9% (95% CI 41.7--54.1). The disease control rate (62% versus 66%) and median DoR (9.2 versus 9.0 months) were similar for both treatment arms.

###### 

Response rates (FAS)

                                                                                                                    ASP8273          Erlotinib/gefitinib
  ---------------------------------------------------------------------------------------------------------- ---------------------- ---------------------
  Best overall response, *n* (%)                                                                                                    
   Complete response                                                                                                   0                      0
   Partial response                                                                                                88 (33.0)             126 (47.9)
   Stable disease                                                                                                  78 (29.2)              48 (18.3)
   Progressive disease                                                                                              17 (6.4)               9 (3.4)
  Overall response rate, *n* (%)                                                                                   88 (33.0)             126 (47.9)
   95% CI, %                                                                                                       27.4, 39.0            41.7, 54.1
   Stratified one-sided *P* value[^a^](#tblfn3){ref-type="table-fn"}                                                  1.0                    NA
  Disease control rate,[^b^](#tblfn4){ref-type="table-fn"}*n* (%)                                                  166 (62.2)            174 (66.2)
   95% CI, %                                                                                                       56.1, 68.0            60.1, 71.9
   Stratified one-sided *P* value[^a^](#tblfn3){ref-type="table-fn"}                                                 0.839                   NA
  Duration of response[^b^](#tblfn4){ref-type="table-fn"}                                                                           
   Events, *n* (%)                                                                                                16/88 (18.2)          24/126 (19.0)
   Censored, *n* (%)                                                                                               72 (81.8)             102 (81.0)
   Median (95% CI), months                                                                                      9.17 (5.45, NE)        9.03 (7.39, NE)
   Range,[^c^](#tblfn5){ref-type="table-fn"} months                                                               0.03+, 9.46+          0.03+, 11.10+
   Stratified one-sided *P* value[^a^](#tblfn3){ref-type="table-fn"}^,^[^d^](#tblfn6){ref-type="table-fn"}           0.780                   NA
   Hazard ratio[^e^](#tblfn7){ref-type="table-fn"} (95% CI)                                                   1.298 (0.661, 2.548)           NA

Stratification factors were ECOG PS (0 and 1 versus 2), *EGFR* mutation type (exon 19 deletion versus exon 21 L8598R), and chosen TKI (erlotinib versus gefintinib).

Based on the Kaplan--Meier estimate.

Plus sign (+) indicates censoring.

*P* value was based on the log-rank test.

Based on the Cox proportional hazards model.

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; *EGFR*, epidermal growth factor receptor; FAS, full analysis set; NA, not applicable; NE, not evaluable; TKI, tyrosine kinase inhibitor.

Safety and tolerability profile of ASP8273
------------------------------------------

Treatment-emergent adverse events (TEAEs) were reported by 251 (94.7%) patients receiving ASP8273 and 261 (99.6%) receiving erlotinib/gefitinib; an overview for both arms is presented in Table [3](#mdz128-T3){ref-type="table"}. Serious TEAEs were reported in 151 (28.7%) patients; 84 (31.7%) in patients receiving ASP8273 and 67 (25.6%) for erlotinib/gefitinib. A total of 74 patient deaths were reported; 31 (5.9%) were due to TEAEs (5.3% of patients and 6.5% receiving ASP8273 or erlotinib/gefitinib, respectively). Two of the TEAEs leading to death were considered related to study drug: acute myocardial infarction and embolic stroke (ASP8273; *n *=* *1) and interstitial lung disease (erlotinib/gefitinib; *n *=* *1). Treatment-emergent AEs led to treatment withdrawal in 67 (12.7%) patients, including 39 (14.7%) receiving ASP8273 and 28 (10.7%) receiving erlotinib/gefitinib. The most common TEAEs leading to withdrawal were increased alanine aminotransferase (*n *=* *13), increased aspartate aminotransferase (*n *=* *9), and interstitial lung disease (*n *=* *7). Treatment-emergent AEs considered related to study drug led to withdrawal in 44 (8.3%) patients, including 27 (10.2%) patients receiving ASP8273 and 17 (6.5%) patients receiving erlotinib/gefitinib.

###### 

Incidence of TEAEs (SAF)

                                                      ASP8273     Erlotinib/ gefitinib     Total
  ------------------------------------------------- ------------ ---------------------- ------------
  TEAEs                                              251 (94.7)        261 (99.6)        512 (97.2)
   Serious TEAE                                      84 (31.7)         67 (25.6)         151 (28.7)
   Grade ≥3 TEAE                                     145 (54.7)        114 (43.5)        259 (49.1)
   TEAE leading to treatment withdrawal              39 (14.7)         28 (10.7)         67 (12.7)
   TEAE leading to dose interruption                 95 (35.8)         74 (28.2)         169 (32.1)
   TEAE leading to dose reduction                    51 (19.2)         51 (19.5)         102 (19.4)
  Deaths                                             39 (14.7)         35 (13.4)         74 (14.0)
   TEAE leading to death                              14 (5.3)          17 (6.5)          31 (5.9)
  Drug-related TEAEs                                 235 (88.7)        246 (93.9)        481 (91.3)
   Serious drug-related TEAE                         46 (17.4)          18 (6.9)         64 (12.1)
   Grade ≥3 drug-related TEAE                        122 (46.0)        67 (25.6)         189 (35.9)
   Drug-related TEAE leading to withdrawal           27 (10.2)          17 (6.5)          44 (8.3)
   Drug-related TEAE leading to dose interruption    83 (31.3)         55 (21.0)         138 (26.2)
   Drug-related TEAE leading to dose reduction       51 (19.2)         50 (19.1)         101 (19.2)
   Drug-related TEAE leading to death                 1 (0.4)           1 (0.4)           2 (0.4)

Data presented as *n* (%).

SAF, safety analysis set; TEAE, treatment-emergent adverse event.

The most common TEAE considered at least possibly related to ASP8273 was diarrhea (59.2% versus 49.2%); skin rash (10.2% versus 70.6%) was the most common TEAE considered related to erlotinib/gefitinib (Table [4](#mdz128-T4){ref-type="table"}). Patients receiving ASP8273 had a higher incidence of hyponatremia (22.6% versus 1.5%), peripheral sensory neuropathy (20.4% versus 0.8%), and fatigue (14.7% versus 7.3%) versus those receiving erlotinib/gefitinib. Compared with those on ASP8273, patients receiving erlotinib/gefitinib had higher incidences of paronychia (25% versus 1%) and stomatitis (19% versus 6%). The most common grade ≥3 TEAEs considered at least possibly related to treatment were hyponatremia (*n *=* *56; 11%), increased alanine aminotransferase (*n *=* *30; 6%), and diarrhea (*n *=* *23; 4%).

###### 

Drug-related TEAEs (SAF)

                                              ASP8273      Erlotinib/gefitinib   Total                                
  ------------------------------------------- ------------ --------------------- ------------ ---------- ------------ -----------
  Any drug-related TEAE in ≥10% of patients                                                                           
   Diarrhea                                   157 (59.2)   16 (6.0)              129 (49.2)   7 (2.7)    286 (54.3)   23 (4.4)
   Skin Rash                                  27 (10.2)    0                     185 (70.6)   19 (7.3)   212 (40.2)   19 (3.6)
   Increased ALT                              49 (18.5)    17 (6.4)              49 (18.7)    13 (5.0)   98 (18.6)    30 (5.7)
   Dry skin                                   26 (9.8)     0                     65 (24.8)    1 (\<1)    91 (17.3)    1 (\<1)
   Nausea                                     52 (19.6)    5 (1.9)               20 (7.6)     1 (\<1)    72 (13.7)    6 (1.1)
   Increased AST                              32 (12.1)    4 (1.5)               40 (15.3)    10 (3.8)   72 (13.7)    14 (2.7)
   Decreased appetite                         44 (16.6)    5 (1.9)               27 (10.3)    1 (\<1)    71 (13.5)    6 (1.1)
   Paronychia                                 3 (1.1)      0                     66 (25.2)    4 (2.0)    69 (13.1)    4 (\<1)
   Stomatitis                                 16 (6.0)     0                     50 (19.1)    2 (\<1)    66 (12.5)    2 (\<1)
   Hyponatremia                               60 (22.6)    54 (20.4)             4 (1.5)      2 (\<1)    64 (12.1)    56 (10.6)
   Fatigue                                    39 (14.7)    9 (3.4)               19 (7.3)     1 (\<1)    58 (11.0)    10 (1.9)
   Peripheral sensory neuropathy              54 (20.4)    1 (\<1)               2 (\<1)      0          56 (10.6)    1 (\<1)

Data presented as *n* (%).

ALT, alanine aminotransferase; AST, aspartate aminotransferase; SAF, safety analysis set; TEAE; treatment-emergent adverse event.

Discussion
==========

In this phase III study, first-line ASP8273 did not reach its primary efficacy end point. The apparent antitumor effect of ASP8273 was numerically less than the control arm and the study was discontinued due to increased toxicity and limited predicted efficacy of ASP8273 relative to erlotinib/gefitinib. Median PFS was 9.3 months with ASP8273 and 9.6 months with erlotinib/gefitinib. The percentage of patients experiencing grade ≥3 TEAEs was higher in those receiving ASP8273 than those receiving erlotinib/gefitinib (54.7% versus 43.5%, respectively), as was the percentage of patients experiencing serious TEAEs (31.7% versus 25.6%). Importantly, while the gastrointestinal (diarrhea, stomatitis, and mucositis) and cutaneous (rash, dry skin, and paronychia) treatment‐related toxicities seen with ASP8273 were similar to those seen with other TKIs \[[@mdz128-B10]\], ASP8273 demonstrated additional, unpredicted toxicities. Specifically, patients treated with ASP8273 were more likely to experience hyponatremia (5.3% versus 0.4%) or peripheral sensory neuropathy (38.5% versus 5.3%) versus those treated with erlotinib/gefitinib. While both toxicities had been reported in patients treated with ASP8273 during previous phase I (NCT02113813) and phase II (NCT02500927) studies, differences between patient populations made it unclear how the incidence of these adverse events would compare with patients receiving erlotinib/gefitinib \[[@mdz128-B8], [@mdz128-B9]\]. Preclinical data suggested ASP8273 penetrated the blood--brain barrier and antitumor activity was observed in brain tumors (data on file), similar to other TKIs including gefitinib, erlotinib, and icotinib \[[@mdz128-B11]\]. Based on data showing limited efficacy and excessive toxicity versus the erlotinib/gefitinib group, this study was discontinued.

Although the *in vitro* and *in vivo* preclinical activity of ASP8273 is similar to osimertinib (data on file), the pyrazine carboxamide-based structure and reactive acrylamide moiety of ASP8273 differs from the pyrimidine-based chemical structure used by other third-generation EGFR-TKIs such as osimertinib and rociletinib \[[@mdz128-B12], [@mdz128-B13]\] and may potentially contribute to differences in efficacy and toxicity. In the current study, both study arms demonstrated lower than expected efficacy and neither treatment resulted in CR. We observed a 48% response rate for patients in the erlotinib/gefitinib arm, despite reports of 65% ORR for erlotinib \[[@mdz128-B14]\] and ∼70% ORR for gefitinib \[[@mdz128-B15]\]. The median PFS of 9.6 months for the comparator arm was also lower compared with historic results for erlotinib in the EURTAC trial (10.4 months) \[[@mdz128-B14]\] and gefitinib (10.9 months) in patients with NSCLC \[[@mdz128-B16]\].

Patient characteristics, especially with respect to *EGFR* mutation profile, may have impacted treatment outcomes and toxicities in the current trial. While previous reports of erlotinib efficacy in NSCLC patients from the EURTAC trial had a similar patient population in terms of sex, age, disease stage, and smoking status, there was a difference in *EGFR* exon 19 deletions (66% versus ∼50%) and *EGFR* exon 21 (L858R) mutations (34% versus 41%), as well as a higher proportion of ECOG PS 2 (14% versus 3%) compared with the current study \[[@mdz128-B14], [@mdz128-B17]\]. A prior report of ASP8273 in patients with NSCLC with *EGFR* mutations investigated using circulating free DNA (cfDNA) as a biomarker of ASP8273 clinical responses and found that ASP8273 decreased *EGFR* T790M cfDNA below the level of detection across all doses, confirming successful on-target inhibition \[[@mdz128-B9]\]. Clinical response to ASP8273 and disease progression was correlated with *EGFR* T790M cfDNA, with a strong concordance between cfDNA detection and local tissue testing (96%, 67%, and 79% for *EGFR* L858R, ex19del, and T790M, respectively) \[[@mdz128-B9]\]. While cfDNA mutation analysis may have proved useful in the current study, the logistics of collecting patient samples from over 500 patients across 23 countries would have been exceedingly difficult.

In conclusion, although ASP8273 was well tolerated and promoted antitumor activity in prior early phase studies in a similar patient population \[[@mdz128-B7]\], ASP8273 did not reach its primary efficacy end point in the current phase III study. At this time, there are no future developmental plans for ASP2783 in NSCLC.
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======================
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